3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Hepatocellular
36
Carcinoma, Non-Small-Cell Lung
17
Small Cell Lung Carcinoma
16
Neoplasms
14
Lung Neoplasms
13
Breast Neoplasms
8
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Prostatic Neoplasms
5
Liver Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Glioblastoma
4
Endometrial Neoplasms
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Carcinoma, Transitional Cell
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Osteosarcoma
2
Mesothelioma, Malignant
2
Mesothelioma
2
Interventions
pembrolizumab
5
fludarabine
2
enfortumab vedotin
2
darolutamide
2
atezolizumab
2
aldesleukin
2
Riluzole
2
Nivolumab
2
Mitomycin
2
Fecal Microbiota Transplantation
2
Cyclophosphamide
2
vedolizumab
1
relatlimab
1
prednylidene
1
olaparib
1
lenvatinib
1
deltacortene
1
cabozantinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tadalafil
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Rivaroxaban
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Prednisone
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Neoplasms
×
atezolizumab
×
Clear all
NCT04624399
2025-11-18
ABACUS-2
Queen Mary University of London
Phase 2
Recruiting
58 enrolled
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled